维普中文期刊产品整合服务
156篇 您的检索式:作者名="Glaspy"
    题名 作者 年代 出处 被引量
1Electroacupuncture for Control of Myeloablative Chemotherapy-Induced Emesis显示文摘Joannie Shen Neil Wenger John Glaspy 2000JAMA2000,284,21:1
2Electroacupuncture for control of myeloablative chemotherapy-induced emesis: a randomized controlled trial显示文摘Shen J Wenger N Glaspy J 2000JAMA2000,284,21:1
3Whole-body 18F-FDG PET imaging {or staging of Hodgkin's disease and lymphoma显示文摘Hoh CK Glaspy J Rosen P 1997J Nucl Med1997,38,3:1
4Darbepoetina alfa given every1or 2 weeks alleviates anaemia associated with cancer chemotherapy显示文摘Glaspy JA Jadeja JS Justice G 2002Br J Cancer2002,87,3:1
5Results of a multicenter, randomized, double-blind,dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignanl melanoma 显示文摘Glaspy J Atkins MB Richards JM 2009Cancer2009,115,22:1
6Darbepoetinα given every 1 or 2 weeks alleviates anemia associated with cancer chemotherapy 显示文摘Glaspy JA Jadeja JS Justice G 2002Br J Cancer2002,87,:1
7RIBBON-l: randomized, double-blind, placebo-controlled, phase III trial of chemother- apy with or without bevacizumab for first-line treatment of hu- man epidermal growth factor receptor 2-negative, locally recur- rent or metastatic breast cancer显示文摘Robert NJ Di e ras V Glaspy J 2011J Clin Oncol2011,29,10:1
8Phase Ⅱ study of two dose schedules of CERA ( continuous erythropoietin receptor activator ) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy显示文摘Hirsh V Glaspy J Mainwaring P Manegold C Ramlau R Eid JE 2007Trials2007,8,:1
9Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum-and nonplatinumbased chemotherapy-a retrospective subanalysis of two large,community-based trials显示文摘Glaspy J Degos L Dicato M 2002Oncologist2002,7,2:1
10Current developments in cancer vaccines and cellular immunotherapy显示文摘Ribes A Butterfield L H Glaspy J A 2003J Clinic Oncol2003,21,12:1
11Role of Iron in optimizing responses of anemic Cancer patients to erythropoietin 显示文摘Glaspy J Cavill I 1999Oncology1999,13,4:1
12Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment显示文摘Chang HR Glaspy J Allison MA 2010Cancer2010,116,18:1
13RIBBON-1 : ran- domized, double-blind, placebo-controlled, phase III tri- al of chemotherapy with or without bevacizumab for first- line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer 显示文摘Robert N J Dieras V Glaspy J 2011J Clin Oncol2011,29,10:1
14Kirschner wire embolization to the heart:an unusual cause of pericardial tamponade显示文摘Goodsett J R Pahl A C Glaspy J N 1999Chest1999,115,:1
15Biology and clinical potential of stem-cell factor 显示文摘Glaspy J Davis MW Parker WR 1996Cancer Chemother Pharmacol1996,38,:1
16Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays显示文摘Comin-Anduix B Gualberto A Glaspy JA 2006Clin Cancer Res2006,12,1:1
17RIBBON- 1: randomized, double-blind, placebo-controlled, phase !I1 trial of chemotherapy with or without bevacizumab for first- line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer显示文摘ROBERT NJ DIERAS V GLASPY J 2011J Clin Oncol2011,29,10:1
18Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia 显示文摘Crawford J Glaspy JA Stoller RG 2005Support Cancer Ther2005,3,1:1
19Do we need a different set of response assessment criteria for tumor immunotherapy 显示文摘Ribas A Chmielowski B Glaspy JA 2009Clin Cancer Res2009,15,23:1
20Erythropoiesis-stimulating agents in oncology 显示文摘Glaspy JA 2008J Natl Compr Cane Netw2008,6,6:1
返回顶部 每页显示:
共8页 首页 上一页 第1页 下一页 末页 /8 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费